Department of Health and Human Services September 2, 2014 – Federal Register Recent Federal Regulation Documents

Notice of Interest Rate on Overdue Debts
Document Number: 2014-20773
Type: Notice
Date: 2014-09-02
Agency: Department of Health and Human Services
Agency Information Collection Activities; Proposed Collection; Public Comment Request
Document Number: 2014-20769
Type: Notice
Date: 2014-09-02
Agency: Department of Health and Human Services, Office of the Secretary
In compliance with section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). The ICR is for extending the use of the approved information collection assigned OMB control number 0990-0330, which expires on 12/31/14. Prior to submitting that ICR to OMB, OS seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
Decision To Evaluate a Petition To Designate a Class of Employees From the Dow Chemical Co. Facility in Walnut Creek, California (Also Known as Pittsburg, CA), To Be Included in the Special Exposure Cohort
Document Number: 2014-20740
Type: Notice
Date: 2014-09-02
Agency: Department of Health and Human Services
NIOSH gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees from the Dow Chemical Co. facility in Walnut Creek, California (also known as Pittsburg, CA), to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows: Facility: Dow Chemical Co. facility. Location: Walnut Creek, California (also known as Pittsburg, CA). Job Titles and/or Job Duties: All employees who worked in any area. Period of Employment: January 1, 1947 through December 31, 1957.
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Fees for Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act
Document Number: 2014-20719
Type: Notice
Date: 2014-09-02
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: 2014-20718
Type: Notice
Date: 2014-09-02
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies
Document Number: 2014-20717
Type: Notice
Date: 2014-09-02
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently HHS-certified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at http:// www.workplace.samhsa.gov.
National Heart, Lung, and Blood Institute; Notice of Meeting
Document Number: 2014-20716
Type: Notice
Date: 2014-09-02
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings
Document Number: 2014-20715
Type: Notice
Date: 2014-09-02
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting
Document Number: 2014-20714
Type: Notice
Date: 2014-09-02
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting
Document Number: 2014-20713
Type: Notice
Date: 2014-09-02
Agency: Department of Health and Human Services, National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed Meeting
Document Number: 2014-20712
Type: Notice
Date: 2014-09-02
Agency: Department of Health and Human Services
Richard C. Theuer; Withdrawal of Food Additive Petition and Citizen Petition
Document Number: 2014-20665
Type: Proposed Rule
Date: 2014-09-02
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or we) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 3A4798) proposing that the food additive regulations be amended to prohibit the use of carrageenan and salts of carrageenan in infant formula. In addition, FDA is also announcing the withdrawal of a citizen petition requesting that the generally recognized as safe (GRAS) regulations be amended to prohibit the use of Chondrus extract (carrageenin) in infant formula.